DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Coherus - 3 Evercore - 1 Roth - 1 it's - 1 CHPT - 1 Wolfe - 1 underperform Wolfe - 1 RBLX - 1
Top related locs:
U.S Organon ChargePoint billings 2Q24 Airbnb Cuban United States
Top related orgs:
Coherus BioSciences - 3 Barclays - 2 Sandoz - 2 Thomson - 2 EV - 1 UBS - 1 Pacific Biosciences - 1 Citi - 1

Search resuls for: "Coherus BioSciences"


7 mentions found


☆ Here are Friday's biggest analyst calls: Nvidia, Zoom, Expedia, Analog Devices, Cava, Roblox, Dick's & more
  + stars: | 2023-11-17 | by ( Michael Bloom | ) www.cnbc.com   time to read: +7 min
Roth MKM downgrades ChargePoint to neutral from buy Roth said it's concerned about weak demand for charging equipment. UBS upgrades Pacific Biosciences to buy from neutral UBS said the biotech company has growth potential. Citi reiterates Microsoft as buy Citi said it's standing by its buy rating on the stock. Morgan Stanley upgrades Analog Devices to overweight from equal weight Morgan Stanley said the bottom is in sight for the semiconductor company. Truist initiates Dick's as buy Truist said in its initiation of the stock that it sees an attractive buying opportunity. "
Persons: Evercore, Roth, it's, CHPT, Wolfe, underperform Wolfe, RBLX, GitLab, Hubbell, Morgan Stanley, Carvana, Raymond James, Cava, Redburn, Piper Sandler, Piper, buybacks, Baird, Truist, Lululemon, Kimberly, Clark Organizations: EV, UBS, Pacific Biosciences, Citi, Microsoft, Barclays, JPMorgan, HSBC, UW, downgrades, Products, Nvidia, Coherus BioSciences, Goods, Zim Locations: ChargePoint, billings, 2Q24
☆ Stocks making the biggest moves premarket: Airbnb, Oracle, American Express and more
  + stars: | 2023-09-05 | by ( Brian Evans | ) www.cnbc.com   time to read: +2 min
Zynex, Coherus BioSciences , Universal Insurance Holdings — Coherus, Zynex and Universal Insurance stock fell on news from S&P 500 Dow Jones indices that the stocks would be moving within small-cap indexes. Coherus is leaving the MidCap 400 for the MidCap 600, while Universal Insurance is leaving the MidCap 600 altogether. American Express — Stock in the credit card giant ticked up 0.5% following an upgrade to outperform from sector perform from RBC earlier Tuesday. The S&P 500 is widely tracked by large index funds, which could create buying pressure on Airbnb's stock in the weeks ahead. Oracle — The software stock added 1.5% in premarket trading following an upgrade to overweight from equal weight by Barclays.
Persons: Dow Jones, Zynex, Airbnb, acquirer Thomas Bravo, —, Alex Harring, Jesse Pound Organizations: New York, Coherus BioSciences, Universal Insurance Holdings, Universal Insurance, RBC, Healthcare, Bloomberg, Oracle, Barclays, Brady, Brady Corporation, FactSet, Warner Bros Locations: Airbnb
☆ Cramer's Lightning Round: Palantir is a buy
  + stars: | 2023-07-10 | by ( Julie Coleman | ) www.cnbc.com   time to read: +1 min
Stock Chart Icon Stock chart icon Rambus's year-to-date stock performance. Stock Chart Icon Stock chart icon Palantir's year-to-date stock performance. Stock Chart Icon Stock chart icon Coherus Biosciences's year-to-date stock performanceCoherus Biosciences : "I've got to tell you, it's a very hard drug to make... Look, it's a good spec, let's just leave it at that." Stock Chart Icon Stock chart icon Commercial Metals's year-to-date stock performance. I like the metal recycling business, and I think it's terrific, second only to Nucor, as far as I'm concerned in that group."
Persons: Coherus, I've Organizations: Metals
☆ Mark Cuban's online pharmacy set to launch Humira biosimilar
  + stars: | 2023-07-05 | by ( Michael Erman | ) www.reuters.com   time to read: +2 min
July 5 (Reuters) - Mark Cuban Cost Plus Drugs, an online pharmacy launched by the billionaire to sell drugs directly to customers at low prices, should soon begin selling Coherus BioSciences's (CHRS.O) biosimilar version of AbbVie Inc's (ABBV.N) blockbuster rheumatoid arthritis drug Humira, Cuban said on Wednesday. Cost Plus Drugs will sell Yusimry for $569.27 plus dispensing and shipping fees. Coherus introduced its Humira biosimilar in the U.S. market this month alongside offerings from other drugmakers such as Boehringer Ingelheim, Sandoz and Organon (OGN.N). Cuban's Cost Plus Drugs aims to drive down the cost of drugs broadly by selling them at a 15% markup over its cost, plus pharmacy fees. Cuban said the company hopes to provide other biosimilar drugs as well.
Persons: Humira, Cuban, Coherus, AbbVie, Michael Erman, David Holmes Organizations: Cuban, Plus, Sandoz, Cuban's, Thomson Locations: U.S, Organon, Cuban
☆ Coherus BioSciences launches biosimilar version of AbbVie's blockbuster Humira
  + stars: | 2023-07-03 | by ( ) www.reuters.com   time to read: +1 min
July 3 (Reuters) - Coherus BioSciences (CHRS.O) said on Monday it has launched a copycat version of AbbVie's (ABBV.N) Humira in the United States at a discount of more than 85% to the blockbuster arthritis drug. Coherus is the latest to launch a biosimilar to Humira in the U.S. market this month after Boehringer Ingelheim, Sandoz and Organon (OGN.N). Coherus said last month it would sell the biosimilar, branded as Yusimry, at $995 per carton, compared with the current list price of Humira of $6,922 per carton. The company has also partnered with billionaire entrepreneur Mark Cuban's pharmaceutical startup to sell the biosimilar at $569.27 plus dispensing and shipping fees. Usually prices fall, often dramatically, when multiple copycat versions of a widely-used medication enter the market.
Persons: Coherus, Boehringer Ingelheim, Mark, Sriparna Roy, Leroy Leo, Shounak Dasgupta, Arun Koyyur Organizations: Coherus BioSciences, Sandoz, Thomson Locations: United States, Humira, U.S, Organon, Bengaluru
☆ 24 'strong-buy' stocks with the highest potential upsides based on consensus price targets from Wall Street's top-performing analysts, according to a fintech company
  + stars: | 2023-07-02 | by ( Laila Maidan | ) www.businessinsider.com   time to read: +1 min
TipRanks compiles stocks that Wall Street's top analysts agree are strong buys. These 24 stocks have the highest upsides, based on averages of the top analysts' price targets. This year's stock market outlook remains uncertain even after a return to a bull market in the second quarter. The bond market is signaling a recession because of an inverted yield curve, while a strong jobs market and rallying stock market are pointing to strength. TipRanks, a fintech company that compiles and analyzes stock-market data, curates a list of the stocks most loved by top analysts.
Persons: Michael Cuggino, Gary Black Organizations: Biosciences, Wall
☆ Stocks making the biggest moves midday: Southwest, Peloton, Tesla, Herbalife and more
  + stars: | 2022-12-27 | by ( Alex Harring | ) www.cnbc.com   time to read: +2 min
Las Vegas Sands , Wynn Resorts — The casino stocks rose following China's announcement that it will end quarantine for international travelers starting Jan. 8. Shares of Las Vegas Sands and Wynn Resorts have outsized exposure to the country given their operations in Macao. B. Riley Financial - Shares of the investment company climbed more than 4% after it released guidance for the fourth quarter. The company said it expects operating adjusted EBITDA of between $90 million and $100 million for the fourth quarter. That is down from the fourth quarter of 2021 but above some previous quarters this year.
0 next >>
Total: 7